Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790516 · ClinicalTrials.gov registry record · NA
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
A NA study, sponsored by Georgetown University.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01790516: Clinical Trial NA study, sponsored by Georgetown University.
NCT01790516 is a NA study that was terminated before completion, run by Georgetown University. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01790516, a NA study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is for patients with newly diagnosed head and neck cancer that cannot be removed by surgery. The purpose of this study is to determine the feasibility of using genetic variations in patients to select the right drug to treat head and neck cancer. Cisplatin and cetuximab (Erbitux)are both approved by the FDA to treat head and neck cancer in combination with radiation therapy. In this study the investigators will test whether genetic differences between patients can be used to pick which of these two drugs a patient should receive. All patients will have a blood sample drawn that will be tested for genetic differences. If patients have genetic differences that correlate with a better outcome from cisplatin they will receive cisplatin with radiation. If patients have genetic differences that do not correlate with a better outcome from cisplatin they will receive cetuximab with their radiation therapy.
Primary Outcome
Feasibility is defined as follows: \- Patients' genetic test results are returned to the treating physician within 3 days
Interventions
- DRUG Cisplatin
- DRUG cetuximab
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-06 |
| Phase | NA |
Why NCT01790516 stopped before completion
NCT01790516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01790516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01790516 about?
NCT01790516 is a clinical study titled "Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer". This study is for patients with newly diagnosed head and neck cancer that cannot be removed by surgery. The purpose of this study is to determine the feasibility of using genetic variations in patients to select the right drug to treat head and neck cancer. Cisplatin and cetuximab (Erbitux)are both...
What is the current status of trial NCT01790516?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2012-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01790516?
The interventions under investigation include: Cisplatin (DRUG), cetuximab (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT01790516?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01790516's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia